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ABSTRACT
Background and the purpose of the study: The objective of the present work was to improve 
bioavailability of cepodoxime proxetil through gastroretentive microballoon formulation. 
Methods: Microballoons of cefpodoxime proxetil were formulated by solvent evaporation and 
diffusion method employing hydroxypropylmethyl cellulose (HPMC) and ethyl cellulose (EC) 
polymers and characterized for  particle size, surface morphology,  incorporation efficiency, 
floating behavior, in vitro drug release study and differential scanning calorimetry (DSC). 
Results: The average particle size of formulated microballoons was in the range of 54.23±2.78-
95.66±2.19µm. Incorporation efficiencies of over 83.77±0.85 % were achieved for the optimized 
formulations. Most of formulations remained buoyant (having buoyancy percentage maximum 
of 81.36±1.96%) for more than 12 hrs indicating good floating behavior of microballoons. 
Higher values of correlation coefficients were obtained with Higuchi’s square root of time 
kinetic treatment heralding diffusion as predominant mechanism of drug release. 
Conclusion: Inferences drawn from in vitro studies suggest that microballoons may be potential 
delivery system for cefpodoxime proxetil with improvement in bioavailability in comparison to 
conventional dosage forms.
Keywords: Floating drug delivery system (FDDS), Solvent evaporation and diffusion method, 
Microparticulate carriers, Differential scanning calorimetry.
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INTRODUCTION
Oral administration is the most convenient and 
preferred mean of drug delivery to the systemic 
circulation. Many attempts have been made to 
develop sustained-release preparations with extended 
clinical effects and reduced dosing frequency. In 
order to develop an oral drug delivery systems, it 
is necessary to optimize both the release rate of the 
drug and the residence time of the system within 
the gastrointestinal tract. Various approaches have 
been used to retain the dosage forms in the stomach 
(1-3), as a way of increasing the gastric residence 
time  (GRT)  including  floating  (4-7),  high  density 
(3), mucoadhesive (8), magnetic (9), unfoldable, 
extendible, or swellable (10), and superporous 
hydrogel systems (11). Both natural and synthetic 
polymers  have  been  used  to  prepare  floating 
microspheres.
Preparation of hollow microspheres or microballoons 
of ibuprofen by the emulsion-solvent diffusion 
method using acrylic polymers has been reported 
(12). These systems allow prolonged residence time 
of dosage forms in the stomach and achievement 
of constant plasma levels; however, it is necessary 
to analyze the gastrointestinal transit behavior in 
human to confirm the suitability of the concept as 
far as the final design is concerned (13). 
Cefpodoxime proxetil (CP) is a prodrug of the third 
generation cephalosporins, which is broad-spectrum 
antibiotic and is administered orally. In human, the 
absolute bioavailability of cefpodoxime proxetil 
administered as a 130mg tablet (equivalent to 100mg 
of cefpodoxime) is about 50% (14). Reported studies 
have pointed possible reasons for low bioavailability 
as: low solubility, typical gelation behavior of CP 
particularly in acidic environments (15-17), and pre-
absorption of luminal metabolism into cefpodoxime 
acid by the action of digestive enzymes (18, 19). It 
has been reported that the absorption of cefpodoxime 
proxetil is optimum at low pH (20). 
The objective of the present work was to improve 
the bioavailability of cefpodoxime proxetil by 
formulating gastroretentive microballoons (hollow 
microspheres) in order to sustain the drug release 
and provide protection from intestinal milieu. In this 
study the influence of various process variables on 
particle size, drug loading, incorporation efficiency 
33Formulation of Cefpodoxime Proxetil Microballoons 34
                                                    
drug release of microballoon formulations was 
investigated.
                    
         
Cefpodoxime proxetil was obtained as a gift sample 
from Lupin laboratories Limited, (Pune, India). 
Hydroxypropyl methyl cellulose, Ethyl cellulose 
and Tween 80 were purchased from Loba Chem 
Private Limited, (Mumbai, India). Ethanol was 
                                                  
India). Dichloromethane was purchased from CDH 
Limited, New Delhi, India. All chemicals/reagents 
used were of analytical grade.
        
                            
Microballoons (hollow microspheres) were prepared 
by the solvent evaporation technique according to 
the reported method. (21). Cefpodoxime proxetil 
(130mg), HPMC and EC (1:1) were dissolved in 
a mixture of alcohol and dichloromethane (1:1) at 
room temperature. The resulting solution was poured 
into 250 ml of distilled water containing 0.01%(v/v) 
tween 80, maintained at room temperature and then 
stirred at different agitation speed for 20 min to allow 
the volatile solvent to evaporate. The microballoons 
                                                 
                               
The size of microballoons was determined using 
a light microscope (BEM-21, Besto Microscope, 
                                                 
micrometer. Scanning electron microscopy (SEM) 
(Philips-XL-20, Netherlands) was performed to 
characterize the surface morphology of the formed 
microballoons. Microballoons were mounted directly 
                                                   
nm) under reduced pressure (0.133 Pa).
                                                 
                    
                                              
microballoons (30mg) were thoroughly triturated 
and suspended in a minimal amount of alcohol, 
suitably diluted with 0.1 N HCl (pH1.2) and 
                                                     
cefpodoxime proxetil (drug content/drug loading) 
was analyzed spectrophotometrically at 263 nm. In 
order to calculate the percentage yield, the prepared 
microballoons were collected and weighed. The 
                                                  
using the following equations:
 
                     
A USP paddle apparatus (Lab India, Mumbai, India) 
using 900 ml of 0.1 N HCl (pH 1.2) maintained 
at 37±0.5 °C with agitation speed of 75 rpm was 
used to study in vitro drug release (22). Samples 
were withdrawn at interval of 2 hrs and analyzed 
spectrophotometrically at 263 nm. The volume was 
replenished with the same amount of fresh dissolution 
                                              
 
              
                                                        
and Higuchi’s equation) were applied on the release 
data of optimized batches to interpret the release 
pattern from matrix system (23-25). Drug released 
                                                       
drug release versus time curve (zero order kinetic 
treatment). Similarly log of % of the unreleased drug 
                                                         
treatment) and percent of the drug release was 
plotted versus square root of time (Higuchi’s Square 
root treatment).
             
Microballoons (0.3g) were spread over the surface 
of a USP (type II) dissolution apparatus (Lab India 
                                                     
                                                    
                                                    
and the settled portions of microballoons were 
recovered separately. The microballoons were dried 
and weighed. Buoyancy percentage was calculated 
as the ratio of the mass of the microballoons 
                                                        
microballoons.
                                       
Thermal analysis was carried out using a DSC 
unit (Pyris 6 DSC, Perkin-Elmer, Netherlands). 
Indium was used to calibrate the temperature scale 
and enthalpic response. Samples were placed in 
aluminum pans and heated at a scanning rate of 
5°C/min from 30 to 400°C. Four samples i.e. pure 
cefpodoxime proxetil, pure HPMC, pure EC and 
cefpodoxime proxetil-loaded microballoons of 
HPMC and EC were analyzed.
                      
                                             
Since ethanol, as a good solvent for the polymers 
which preferentially diffuses out of dispersed 
droplets (organic phase) into aqueous phase was 
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and the organic phase. The yield of microballoons 
was a function of diffusion of solvents in the organic 
phase into aqueous phase. It has been reported that 
when the rate of the diffusion rate of solvent out of 
emulsion droplet is too slow, microspheres coalesced 
together. Conversely, when the diffusion of solvent 
is too fast, the solvent may diffuse into the aqueous 
phase before stable emulsion droplets are developed, 
causing aggregation of embryonic microsphere 
droplets (26). Results of this study showed that the 
formation of microballoons is a function of process 
variables such as polymer concentration, solvent 
composition, rate of agitation and temperature. 
From the results of this study it was found 
that average particle size and wall thickness of 
microballoons increased by increase in the polymer 
concentration as it is apparent from observations of 
formulations P1 to P4 having average particle size 
in the range of 54.23±2.78-95.66±2.19 μm (Table 
1). This may be attributed to increased viscosity of 
medium at higher polymer concentration resulting 
                                                    
was also diminished at higher viscosities (27, 28). 
Which results in the formation of larger particles. 
It was obvious that speed of the rotation of the 
propeller affects the yield and size distribution of 
microballoons (Table 1). When the rotation speed 
of propeller was fast (1000 rpm), the average 
particle size decreased and their morphological 
characteristics were maintained. At low (250 rpm) 
                                                    
form stable emulsion droplets, as a consequence 
larger droplets were formed and they were 
aggregated eventually. Thus optimum rotation speed 
for formulations of this study was medium i.e.500 
                                                  
                                                  
composition was found to be a vital factor in the 
formulation process governing the yield and particle 
size of microballoons (Table 1). As the amount of 
dichloromethane increased, the average particle 
size of microballoons was increased. Since alcohol 
preferentially diffused out of emulsion droplets, 
dichloromethane became a major constituent of 
the internal organic phase. The polymer, not being 
soluble at the interface between dichloromethane 
and aqueous phase, started to solidify around 
dichloromethane rich emulsion droplets and the 
volume of dichloromethane within the droplets 
became a size determining factor. The content of 
dichloromethane also affected the morphology 
of microballoons and best results were obtained 
at the ratio of alcohol to dichloromethane of 2:1 
(formulation P12).
The temperature of the dispersing medium was an 
important factor in the formation of microballoons, 
because it controls the rate of evaporation of the 
solvents (Table1). At lower temperature (8-10°C), 
the prepared microballoons had irregularly shaped 
surface morphology and the shell was translucent 
Formula-tion Code
Components
Yield (%) Drug Loading (μg/mg)  IE (%)
Percentage
buoyancy Polymer ratio‡ Solvent ratio Mean particle size (μm)
P 1 1:1 1:1 54.23±2.78 74.25±1.85 116.0±1.25 78.29±1.13 73.61±2.02
P 2 1:2 1:1 73.81±3.15 76.32±1.95 118.7±1.68 82.36±1.19 74.32±2.08
P 3 1:4 1:1 88.23±4.05 78.21±1.65 117.6±1.81 83.62±0.86 76.62±2.20
P 4 1:6 1:1 95.66±2.19 76.11±1.30 121.1±1.53 83.77±0.85 78.11±1.96
P 5 2:1 1:1 34.17±4.65 75.21±1.39 113.5±1.92 77.61±0.68 73.87±2.32
P 6 4:1 1:1 58.80±4.06 73.68±1.72 115.3±1.26 77.2±1.26 78.68±2.87
P 7 6:1 1:1 73.68±4.06 72.58±1.73 125.5±1.63 82.78±1.09 81.36±2.15
P 9* 1:2 1:1 71.06±3.82 76.32±1.14 114.0±1.58 79.11±1.66 76.32±1.84
P-10* 1:2 1:1 56.10±2.62 72.39±1.92 114.9±1.46 75.63±1.38 74.21±2.10
P 11 1:2 1:1 73.81±3.15 76.32±1.95 118.7±1.83 82.36±1.19 74.32±2.08
P 12 1:2 2:1 67.49±3.19 78.62±1.58 105.4±1.49 75.32±0.98 71.25±2.39
P 13 1:2 1:2 78.71±3.64 76.92±1.53 111.9±1.73 78.25±0.72 72.84±3.11
P 15† 1:2 2:1 71.91±3.49 78.41±1.93 110.4±1.85 78.68±1.04 74.32±1.77
P 16† 1:2 2:1 62.05±3.86 74.21±1.03 108.6±1.24 73.24±0.96 76.29±2.10
* Formulations were prepared at varying agitation speed (250, 500 and 1000 rpm)
† Formulations were prepared at varying temperatures
‡ Polymer ratio (HPMC: EC)
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during the process, due to the slower rate of 
diffusion of ethanol. At higher temperatures, the 
shell of the microballoons was very thin and some of 
them were broken (formulation P16) which might be 
due to the faster diffusion of alcohol of the droplet 
into aqueous phase and immediate evaporation of 
dichloromethane after introduction into the medium. 
The optimum temperature for present study, to form 
                                                    
room temperature (formulation P15). 
                                 
By observation it was apparent that microballoons 
composed of HPMC at higher ratio (formulations 
P5, P6 and P7) were smaller in size as compared 
to microballoons with high EC content (Table1). 
Scanning electron micrograph (Fig 1) revealed that 
by using solvent diffusion and evaporation method 
spherical shaped microballoons with smooth outer 
surface and hollow core were formed. Incorporation 
                                                     
of process variables as well as the physicochemical 
properties of drug. It was observed that variation 
                                                 
                                                     
polymer concentration restricted the movement 
of drug from polymer matrix into aqueous phase. 
Solubility of drug in organic solvents also played an 
important role in determination of the incorporation 
Formulation Code
Zero order* First order* Higuchi’s square root of time*
K0 r2 K1 r2 KH r2
P-2 0.1215 0.909 10.517 0.983 0.0347 0.990
P-3 0.1597 0.921 23.008 0.954 0.0447 0.966
P-9 0.1242 0.900 11.517 0.983 0.0357 0.991
P-12 0.1211 0.883 10.312 0.964 0.0351 0.981
P-15 0.1215 0.909 10.5173 0.981 0.0.347 0.993
* K0 (h-1), K1 (h-1) and KH (h-1/2) are release rate constants for Zero, First and Higuchi’s kinetic treatment, respectively.
         Kinetic treatment of drug release data of cefpodoxime proxetil microballoons.
                                                    
both alcohol and dichloromethane. The drug was 
                                                       
phase was minimum. The increase in polymer 
concentration had no impact on the percentage yield 
                                                      
effect from any of the preparations. Guiziou        
                                                   
from poly (lactide) microspheres prepared by solvent 
evaporation method (29). Results indicate that 
proportion of polymers in formulation was the key 
factor governing release of drug from microballoons. 
As the concentration of polymer increased, there was  
an increased in diffusional path length. This may 
decrease the overall drug release from the polymer 
matrix. Formulation comprised of EC in higher 
proportion exhibited much retarded drug release as 
compared to HPMC formulations (Figs 2A and 2B). 
                                                 
was agitation speed. At higher rotation speed smaller 
microballoons were formed resulting in higher drug 
                                                         
composition was observed on the in vitro release of 
cefpodoxime proxetil (Fig. 4). It is apparent that the 
drug release, from microballoons prepared at high 
temperatures, was slightly higher by virtue of thin 
shell of the microballoons (Fig 5).
                                                   
obtained in the case of Higuchi’s square root of 
A B
          Scanning electron micrograph of microballoons. A. Outer surface of microballoons, B. Inner surface of a broken half of a 
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          Overlap Differential Scanning Calorimetry (DSC) thermogram of pure drug, polymers and microballoon formulation.
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time kinetic treatment (Table 2) which may indicate 
that diffusion was predominant mechanism of drug 
release. 
The microballoons were spread over the surface 
                                                
and the settled portions of microballoons were 
recovered separately. It was obvious from results 
that most of the prepared microballoons remained 
                                                 
the drug in dissolution media in sustained manner 
(Table1). The result also showed a tendency that 
                                                     
time. It should be noted, however, that the in vivo 
situation can be quite different and the residence 
time may vary widely depending on the phase of 
gastric motility.
DSC thermograms of microballoons along with 
those of drug and polymers are depicted in Fig 6. 
DSC thermogram of the cefpodoxime proxetil-
loaded microballoons revealed that the drug existed 
in the amorphous state in the shell of microballoons, 
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The microballoons so prepared will remain buoyant 
                                                       
proxetil in sustained fashion. Inferences drawn from 
in vitro studies suggest that microballoons may 
prove as potential delivery system for cefpodoxime 
proxetil by improving bioavailability in comparison 
to conventional dosage forms. 
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